Literature DB >> 27812733

Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review.

Feras Oskan1,2, Gerd Becker3,4, Martin Bleif3,4.   

Abstract

The toxicity of stereotactic body radiation therapy in the central chest remains an unsettled issue. The collected data concerning the observed complications are poorly understood and are limited in their quantity and quality, thus hampering a precise delineation of treatment-specific toxicity. The majority of complications scored as toxicity grade 5, namely respiratory failure and fatal hemoptysis, are most likely related to multiple competing risks and occurred at different dose fractionation schemas, e. g., 10-12 fractions of 4-5 Gy, 5 fractions of 10 Gy, 3 fractions of 20-22 Gy, and 1 fraction of 15-30 Gy. Further investigations with longer follow-up and more details of patients' pretreatment and tumor characteristics are required. Furthermore, satisfactory documentation of complications and details of dosimetric parameters, as well as limitation of the wide range of possible fractionation schemes is also warranted for a better understanding of the risk factors relevant for macroscopic damage to the serially organized anatomic structure within the central chest.

Entities:  

Keywords:  Heart; Hemoptysis; Lung cancer; Organs at risk; Risk factors

Mesh:

Year:  2016        PMID: 27812733     DOI: 10.1007/s00066-016-1063-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  47 in total

1.  Central-airway necrosis after stereotactic body-radiation therapy.

Authors:  Michael N Corradetti; Andrew R Haas; Ramesh Rengan
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

2.  Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study.

Authors:  Ronald C McGarry; Lech Papiez; Mark Williams; Tia Whitford; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-22       Impact factor: 7.038

3.  Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.

Authors:  Kristin Karlsson; Jan Nyman; Pia Baumann; Peter Wersäll; Ninni Drugge; Giovanna Gagliardi; Karl-Axel Johansson; Jan-Olov Persson; Eva Rutkowska; Owe Tullgren; Ingmar Lax
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

4.  Stereotactic body radiotherapy for lung tumors at the pulmonary hilum.

Authors:  Yoshiko Oshiro; Takashi Aruga; Koji Tsuboi; Kan Marino; Ryusuke Hara; Yasushi Sanayama; Jun Itami
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

5.  Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial.

Authors:  Samuel Bral; Thierry Gevaert; Nadine Linthout; Harijati Versmessen; Christine Collen; Benedikt Engels; Douwe Verdries; Hendrik Everaert; Nicolas Christian; Mark De Ridder; Guy Storme
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-12       Impact factor: 7.038

6.  Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

Authors:  Kevin L Stephans; Toufik Djemil; Claudiu Diaconu; Chandana A Reddy; Ping Xia; Neil M Woody; John Greskovich; Vinit Makkar; Gregory M M Videtic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

7.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.

Authors:  Robert Timmerman; Lech Papiez; Ronald McGarry; Laura Likes; Colleen DesRosiers; Stephanie Frost; Mark Williams
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

8.  Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Authors:  Jonathan Feddock; Susanne M Arnold; Brent J Shelton; Partha Sinha; Gary Conrad; Li Chen; John Rinehart; Ronald C McGarry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-19       Impact factor: 7.038

Review 9.  Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Authors:  M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Journal:  Ann Oncol       Date:  2011-11-04       Impact factor: 32.976

Review 10.  Complications from Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Kylie H Kang; Christian C Okoye; Ravi B Patel; Shankar Siva; Tithi Biswas; Rodney J Ellis; Min Yao; Mitchell Machtay; Simon S Lo
Journal:  Cancers (Basel)       Date:  2015-06-15       Impact factor: 6.639

View more
  8 in total

1.  Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Authors:  Feras Oskan; Yvonne Dzierma; Stefan Wagenpfeil; Christian Rübe; Jochen Fleckenstein
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.

Authors:  Carsten Nieder; Dirk De Ruysscher; Laurie E Gaspar; Matthias Guckenberger; Minesh P Mehta; Patrick Cheung; Arjun Sahgal
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

3.  Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.

Authors:  S G C Kroeze; C Fritz; L Basler; E Gkika; T B Brunner; A L Grosu; M Guckenberger
Journal:  Strahlenther Onkol       Date:  2019-02-08       Impact factor: 3.621

4.  Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients.

Authors:  Erkan Topkan; Ugur Selek; Yurday Ozdemir; Ali A Besen; Ozan C Guler; Berna A Yildirim; Huseyin Mertsoylu; Alper Findikcioglu; Ozgur Ozyilkan; Berrin Pehlivan
Journal:  J Oncol       Date:  2018-11-01       Impact factor: 4.375

5.  Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Nicholas G Zaorsky; Bing-Shen Sun; Lei Zhu; Yong-Chun Song; Feng-Tong Li; Yang Dong; Jing-Sheng Wang; Hua-Ming Chen; Xu-Yao Yu; Zhi-Yong Yuan
Journal:  Cancer Sci       Date:  2019-09-09       Impact factor: 6.716

Review 6.  Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors.

Authors:  Dawn Owen; Terence T Sio
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

7.  Successful Surgical Resection following Bronchial Artery Embolization in a Case of Lung Cancer Complicated with Massive Hemoptysis.

Authors:  Hironori Sadamatsu; Koichiro Takahashi; Hiroshi Inoue; Hitomi Umeguchi; Satoko Koga; Hideo Kuroki; Michiaki Akashi; Masato Kato; Naoko Sueoka-Aragane
Journal:  Case Rep Oncol       Date:  2018-02-28

8.  Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients.

Authors:  Barbara Schuster; Anna Ellmann; Theresa Mayo; Judith Auer; Matthias Haas; Markus Hecht; Rainer Fietkau; Luitpold V Distel
Journal:  BMC Geriatr       Date:  2018-05-04       Impact factor: 3.921

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.